Valuation: Mylan N.V.

Market Cap 20.14B 17.6B 16.24B 14.97B 28.21B 1,939B 28.84B 194B 76.33B 950B 75.62B 73.96B 3,269B P/E 2026 *
74.2x
P/E 2027 * 27.4x
Enterprise Value 32.32B 28.25B 26.06B 24.03B 45.28B 3,113B 46.29B 312B 123B 1,524B 121B 119B 5,248B EV / Sales 2026 *
2.19x
EV / Sales 2027 * 2.07x
Free-Float
92.23%
Yield 2026 *
2.94%
Yield 2027 * 3.02%
Manager TitleAgeSince
Chief Executive Officer 63 2023-03-31
Director of Finance/CFO 59 2026-05-07
Chief Administrative Officer 42 2025-08-18
Director TitleAgeSince
Director/Board Member 78 2020-11-15
Director/Board Member 78 2020-11-15
Director/Board Member 62 2020-11-15
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+1.37% - - 20.14B
+0.85%-0.80%+52.79%+159.97% 1,051B
+1.23%-1.53%+54.58%+59.41% 609B
+0.04%+2.58%+34.47%+84.84% 450B
+0.78%-0.71%+29.28%+23.25% 330B
+1.41%+0.58%+35.44%+40.53% 284B
-0.27%-1.87%+22.34%+19.92% 263B
-1.76%+2.37%-20.43%-38.01% 223B
-1.42%+0.80%+24.27%+57.85% 198B
-1.48%+3.43%+24.08%+70.06% 167B
Average +0.13%+0.54%+28.54%+53.09% 397.23B
Weighted average by Cap. +0.38%+0.02%+37.51%+78.76%

Financials

2026 *2027 *
Net sales 14.77B 12.91B 11.91B 10.98B 20.7B 1,423B 21.16B 142B 56.01B 697B 55.48B 54.27B 2,399B 15.04B 13.14B 12.13B 11.18B 21.07B 1,448B 21.54B 145B 57.01B 709B 56.47B 55.23B 2,442B
Net income 13M 11.36M 10.48M 9.66M 18.21M 1.25B 18.61M 125M 49.27M 613M 48.81M 47.74M 2.11B 498M 435M 401M 370M 697M 47.91B 713M 4.8B 1.89B 23.47B 1.87B 1.83B 80.78B
Net Debt 12.19B 10.65B 9.83B 9.06B 17.07B 1,174B 17.45B 117B 46.2B 575B 45.77B 44.76B 1,979B 11.03B 9.64B 8.9B 8.2B 15.45B 1,062B 15.8B 106B 41.82B 520B 41.43B 40.52B 1,791B
Logo Mylan N.V.
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-